Details of the Drug Combination

General Information of Drug Combination (ID: DCVMQB8)

Drug Combination Name
Picoplatin Altretamine
Indication
Disease Entry Status REF
Cutaneous melanoma Investigative [1]
Component Drugs Picoplatin   DM0PIY6 Altretamine   DMKLAYG
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SK-MEL-28
Zero Interaction Potency (ZIP) Score: 5.74
Bliss Independence Score: 7.13
Loewe Additivity Score: 0.73
LHighest Single Agent (HSA) Score: 0.21

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Picoplatin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [2]
Ovarian cancer 2C73 Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [2]
Small-cell lung cancer 2C25.Y Phase 3 [2]
Indication(s) of Altretamine
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Approved [3]
Altretamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Breaker [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Astrocytoma DCK9OW7 SNB-19 Investigative [5]
Clear cell renal cell carcinoma DCAWMHB 786-0 Investigative [5]
Papillary renal cell carcinoma DCO7VJ3 ACHN Investigative [5]
Carcinoma DCO1OFG RXF 393 Investigative [6]
Colon carcinoma DC6SBUM KM12 Investigative [6]
Invasive ductal carcinoma DCV4OQB HS 578T Investigative [6]
Adenocarcinoma DC6VC4X HT29 Investigative [1]
Amelanotic melanoma DCKH8ME M14 Investigative [1]
Cutaneous melanoma DC96QT0 SK-MEL-5 Investigative [1]
High grade ovarian serous adenocarcinoma DCYH84J NCI\\/ADR-RES Investigative [1]
Lung adenocarcinoma DC956K3 MDA-MB-231 Investigative [1]
Malignant melanoma DCP0EUQ UACC62 Investigative [1]
Melanoma DCYXGCE SK-MEL-2 Investigative [1]
Mixed endometrioid and clear cell carcinoma DC7IGR3 IGROV1 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7112).
4 Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.
5 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.